Jakub Hlavka

Title(s)Research Assistant Professor
SchoolUSC Sol Price School of Public Policy
Address635 Downey Way
University Park Campus
Los Angeles CA 90089
Phone+1 213 821 6113
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Pardee RAND Graduate School, Santa Monica, CAPhDPublic Policy Analysis: Health Economics
    Georgetown University , Washington D.C.MA International Affairs, Technology Policy
    University of Economics, Prague, Czech RepublicBSc.International Trade
    Collapse Awards and Honors
    Aspen Institute Central Europe2017Aspen Young Leader
    St Gallen Symposium2015Leader of Tomorrow

    Collapse Overview 
    Collapse Overview
    Jakub Hlávka, PhD, is a Research Assistant Professor in the Health Policy and Management Department of the Price School of Public Policy and Schaeffer Center for Health Policy & Economics, University of Southern California. His research interests include innovative payment for healthcare, health system reform, emerging therapies and the study of inequality.

    Prof. Hlávka completed his PhD at the Pardee RAND Graduate School where he studied innovative payment approaches for emerging treatments like cell and gene therapies, specializing in cardiovascular conditions. At RAND, he also co-authored studies in national security, aerospace and emerging technologies and has served in research and consulting roles at the intersection of research finance, intellectual property, national security and governance at Genentech, the Fraunhofer Society, RAND Europe, Czech Government and the Czech Ministry of Finance. Dr. Hlávka holds degrees from Georgetown University and the University of Economics in Prague.

    Prof. Hlávka teaches graduate-level health economics at the Sol Price School of Public Policy at USC.

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Models. Value Health. 2022 Jul 05. Hlávka JP, Tysinger B, Yu JC, Lakdawalla DN. PMID: 35803845; PMCID: PMC9813270.
      View in: PubMed   Mentions:    Fields:    
    2. Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. Pharmacoeconomics. 2022 07; 40(7):647-652. Hl?vka JP, Lavelle TA, Neumann PJ, Lin PJ. PMID: 35553029.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. The economics of alternative payment models for pharmaceuticals. Eur J Health Econ. 2021 Jun; 22(4):559-569. Hl?vka JP, Yu JC, Goldman DP, Lakdawalla DN. PMID: 33725260; PMCID: PMC8169601.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Appl Health Econ Health Policy. 2020 10; 18(5):669-677. Hl?vka JP, Mattke S, Wilks A. PMID: 32090302; PMCID: PMC7483141.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. Rand Health Q. 2019 May; 8(3):2. Hlavka JP, Mattke S, Liu JL. PMID: 31205802; PMCID: PMC6557037.
      View in: PubMed   Mentions: 25  
    6. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar; 7(4):3. Mulcahy AW, Hlavka JP, Case SR. PMID: 30083415; PMCID: PMC6075809.
      View in: PubMed   Mentions: 49  
    7. A New Model for Pricing Drugs of Uncertain Efficacy. NEJM Catalyst. 2018. Erik Snowberg Dana P. Goldman, Karen Van Nuys, Wei-Han Cheng, Jakub P. Hlávka, Luca Pani, Sylvain Chassang . View Publication.
    8. Toward a Sustainable Blood Supply in the United States. 2016. Andrew W Mulcahy, Kandice Kapinos, Brian Briscombe, Lori Uscher-Pines, Ritika Chaturvedi, Spencer R Case, Jakub Hlávka, Benjamin M Miller. View Publication.
    Jakub's Networks
    Concepts (14)
    Derived automatically from this person's publications.
    Co-Authors (3)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department